^
    Back
    Association details:
    Biomarker:SP140 overexpression
    Cancer:Melanoma
    Drug Class:CTLA4 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Immunother Cancer
    Title:

    SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response

    Published date:
    12/13/2022
    Excerpt:
    Examining the dataset of metastatic melanoma patients who underwent CTLA-4 blockade immunotherapy, we found significantly more favorable survival in patients who had high SP140 levels (n=12) than in patients with low levels of SP140 (n=28) (log-rank test, p=4.98E-3).
    DOI:
    10.1136/jitc-2022-005088